Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.50 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17492516 | 0.86 | BRD4 (0.50) | BRD4CA12CA1CA2CA9 | |
| SCHEMBL21191092 | 0.86 | BRD4 (0.48) | BRD4CA1CA2MEN1KMT2A | |
| SCHEMBL17492779 | 0.83 | BRD4 (0.39) | BRD4CA1CA2MAPTALDH1A1 | |
| SCHEMBL17492543 | 0.80 | P2RX3 (0.52) | BRD4P2RX3CA12CA1CA2 | |
| SCHEMBL17492848 | 0.78 | GSK3B (0.45) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL21190848 | 0.75 | BRD4 (0.44) | BRD4P2RX3CA12CA1CA2 | |
| SCHEMBL17197474 | 0.75 | MAPT (0.45) | MEN1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL30045214 | 0.75 | MAPT (0.45) | MEN1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL16009256 | 0.74 | BRD4 (0.51) | BRD4CA12CA1CA2CA9 | |
| SCHEMBL1678837 | 0.73 | L3MBTL1 (0.50) | P2RX3MEN1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3539962-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2970330-B1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| US-10035800-B2 | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | ABBVIE INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160039821-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035800-B2 | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | BRD1, BRD3, BRD4 | BRD4 3/4885P2RX3 671/4885CA12 1495/4885 |
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | BRD4 2/4885P2RX3 1857/4885CA12 2677/4885 |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | BRD4 2/4885P2RX3 1857/4885CA12 2677/4885 |
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | BRD4 2/4885P2RX3 1857/4885CA12 2677/4885 |
| US-20160039821-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | BRD4 2/4885P2RX3 1688/4885CA12 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.